Please note!

This fact brief was originally published as an experiment to test the concepts behind fact briefs.

Readers should be aware that while there is still a lot of useful information in fact briefs like this one, not all of them reflect Gigafact's current methods and standards for fact briefs. If you come across any that you feel are out of date, don't hesitate to contact us at support@gigafact.org.

FACT BRIEF

Is Johnson & Johnson behind on manufacturing goals for its COVID-19 vaccine?

Wednesday, February 24, 2021

By Remaya Campbell

Copy link

Copy featured image

YES

Required U.S. regulatory approval could come as soon as Feb. 27 for a single-dose COVID-19 vaccine developed by Johnson & Johnson, but manufacturing of the vaccine is running behind schedule.

The New York Times reported on Feb. 24 that the company will have four million does ready to ship at the end of February. Originally the company promised triple that volume by then. By the end of March the company will still be 17 million doses short of the original goals laid out last August, when the U.S. government ordered 100 million does of the vaccine. The company “insists” it will fulfill the total $1 billion order by the end of June, the Times said.

Federal regulators released analyses confirming that the new vaccine is safe, “with noticeably milder side effects than the Pfizer and Moderna vaccines, and without any reports of severe allergic reactions like anaphylaxis,” the Times added.

This fact brief is responsive to conversations such as this one.

Sources

New York Times New York Times: New analyses show Johnson & Johnson’s one-dose vaccine works well

Food and Drug Administration: Advisory committee meeting materials, Feb. 26, 2021

Center for Infectious Disease Research and Policy University of Minnesota: J&J COVID vaccine heads to FDA for emergency use decision

U.S. Department of Health and Human Services Department of Health and Human Services: HHS, DOD collaborate with Johnson & Johnson to produce millions of COVID-19 investigational vaccine doses

ABOUT THE CONTRIBUTOR

Gigafact

Between 2020 and 2022, under close editorial supervision, Gigafact contracted a group of freelance writers and editors to test the concepts for fact briefs and provide inputs to our software development process. We call this effort Gigafact Foundry. Over the course of these two years, Gigafact Foundry writers published over 1500 fact briefs in response to claims they found online. Their important work forms the basis of Gigafact formats and editorial guidelines, and is available to the public on Gigafact.org. Readers should be aware that while there is still a lot of relevant information to be found, not all fact briefs produced by Gigafact Foundry reflect Gigafact's current methods and standards for fact briefs. If you come across any that you feel are out of date and need to be looked at with fresh eyes, don't hesitate to contact us at support@gigafact.org.

FACT BRIEF BY

Latest fact briefs

About fact briefs published on Gigafact

Fact briefs are short, credibly sourced summaries that offer “yes/no” answers in response to claims found online. They rely on publicly available, often primary source data and documents. Fact briefs are created by contributors to Gigafact —a nonprofit project looking to expand participation in fact-checking and protect the democratic process. See all fact briefs here.